The Aspen Eli Lilly Partnership

In August 2023, Aspen Pharmacare and Eli Lilly announced a distribution and promotion agreement. The headline was that Aspen would distribute Eli Lilly's tirzepatide, marketed globally as Mounjaro, in South Africa and the rest of sub-Saharan Africa. At the time the announcement received modest coverage outside the pharmaceutical press. It turned out to be one of the most consequential commercial decisions in recent SA pharmaceutical history.

This is the story of why the partnership was structured the way it was and what it has meant for SA patients.

Who Aspen Is

Aspen Pharmacare is the largest pharmaceutical manufacturer in Africa, JSE listed, with revenues of tens of billions of rand. The company manufactures pharmaceuticals at multiple South African sites, including injectable manufacturing facilities that have produced medications for various global pharmaceutical companies over decades. Aspen also has long established commercial relationships with SA pharmacies, hospitals, and prescribers.

For a multinational like Eli Lilly looking to enter the sub-Saharan African market with a major new product, partnering with Aspen offered something difficult to replicate: deep local distribution scale, regulatory familiarity, and manufacturing infrastructure.

The Structure Of The Agreement

The 2023 agreement was specifically a distribution and promotion arrangement. Under this structure, Eli Lilly retains ownership of the molecule, the trial data, the patents, and the global pricing strategy. Aspen handles SA-specific commercial activities: importing, distribution, pharmacy relationships, prescriber education, and pricing within the parameters Eli Lilly sets.

This is different from a licensing or manufacturing arrangement. Aspen does not manufacture tirzepatide. Production remains with Eli Lilly at their global facilities. What Aspen contributes is the operational backbone for getting the product to SA patients.

Stephen Saad, Aspen Group CEO, framed it at the time as Aspen serving as Lilly's "chosen partner" for the region. Aspen Group Senior Executive Stavros Nicolaou has been the public face of much of the commercial communication around the rollout.

What The Partnership Made Possible

Speed of rollout

SAHPRA approved Mounjaro for type 2 diabetes in December 2024. Within weeks, the medication was on pharmacy shelves nationwide. This pace would not have been possible without an established distributor with existing pharmacy relationships. New entrants to a market often take months to achieve full distribution. Aspen achieved it in weeks.

Pharmacist familiarity

Aspen has decades of relationships with SA pharmacists. When a new Aspen product launches, the pharmacist network is informed, trained, and equipped to dispense and counsel patients on the medication. For Mounjaro, this meant patients walking into pharmacies in early 2025 encountered pharmacists who already knew what the medication was and how to handle it.

KwikPen registration

The KwikPen multi-dose injection device used in SA is the same device used in other Eli Lilly markets. Aspen registered the KwikPen specifically with SAHPRA, which was the regulatory framework for ongoing supply. CEO Stephen Saad has indicated that the KwikPen registration in SA is the platform Aspen will use to expand registrations across sub-Saharan Africa.

Prescriber education

Specialist physician engagement is part of any successful pharmaceutical launch. Aspen organised events, distributed clinical materials, and supported SA endocrinologists, diabetologists, and obesity specialists with information about the medication and the trial programme. This was particularly important for the weight management indication, which was newer territory for many SA prescribers.

The Manufacturing Question

One of the recurring questions about the Aspen partnership concerns manufacturing. Aspen has substantial manufacturing capability and has been involved in producing pharmaceuticals for other multinationals (most notably during the COVID-19 pandemic). Could Aspen eventually manufacture tirzepatide locally?

The answer for now is no. The current agreement is distribution and promotion only. Manufacturing remains with Eli Lilly. Local manufacturing would require a separate agreement, would involve technology transfer, and would face regulatory complexity. Eli Lilly has not publicly indicated plans to license local manufacturing of tirzepatide.

The implications for SA patients are operational rather than commercial. Supply of Mounjaro to SA depends on Eli Lilly's global manufacturing capacity. Periodic supply pressure has affected other markets where tirzepatide demand has outstripped supply. SA has so far avoided major supply issues, partly because Aspen has managed allocation effectively.

The Sub-Saharan Africa Plan

In early 2026, Aspen CEO Stephen Saad told investors that the SA KwikPen registration provided "an opportunity now to register the product across sub-Saharan Africa". Registrations were expected from as early as 2026.

This is commercially significant. Sub-Saharan Africa is one of the last major regional markets where GLP-1 medications have not been widely available. The region also has growing rates of type 2 diabetes and obesity. Aspen sees opportunity in being first to market across multiple African countries with the strongest available GLP-1 medication.

For SA patients specifically, the regional expansion does not directly affect access. But the strategic positioning matters. Aspen has reason to invest in maintaining strong distribution scale and supply reliability in SA, because the SA experience is the template for the regional expansion. SA patients benefit from being in what is effectively the demonstration market for Aspen's broader Africa strategy.

What The Partnership Has Not Solved

The partnership has solved availability but not affordability. Mounjaro remains expensive in SA, at R3,400 to R5,500+ per month depending on dose. This is partly because Eli Lilly sets the pricing within parameters consistent with their global strategy, partly because there is no generic competition, partly because the SA medical aid system has not fully integrated coverage for weight management.

Aspen has some influence on pricing within negotiated bands but cannot unilaterally cut prices below what Eli Lilly accepts. The price reductions that competitor Wegovy underwent in March 2026 (driven by Novo Nordisk's strategic decisions) have not been matched by Mounjaro to the same degree.

Whether Aspen will eventually press for price reductions remains to be seen. Generic competition for tirzepatide is years away (key SA patents not expiring until the 2030s), so the immediate pricing pressure comes from other branded alternatives rather than from generics.

The Broader Context

The Aspen-Lilly partnership is part of a broader pattern of multinational pharmaceutical companies partnering with strong local distributors in emerging markets rather than building direct local operations. The model trades some commercial margin for speed and reliability of market entry.

For SA patients, the practical effect has been a major new medication becoming available faster, at wider distribution, and with better commercial support than would have happened otherwise. The cost has not been the cheapest possible pricing. The trade-off has, on balance, been worthwhile.